CUTISS AG

CUTISS is a late-stage clinical TechBio, the only company transforming skin surgery and advanced dermatology with revolutionary skin tissue therapeutics. We are developing the first BIO personalized and automated skin tissue therapeutics, solution for patients that require skin surgery for a large spectrum of indications, from burns to aesthetics. Our lead product denovoSkin™ is a first-in-class, bioengineered, personalized skin tissue therapeutic designed to improve patient outcomes and redefine the standard of care in skin surgery. Currently in Phase 3 clinical trials in the European Union, it has Orphan Drug Designation for the treatment of burns from Swissmedic, EMA, and US FDA. CUTISS is also pioneering the TECH automation of skin tissue bioengineering, developing the world’s first machine to fully automate manufacturing, securing scalability, accessibility and cost-efficiency and allowing for an attractive unit economics. Our propriertary TECHBIO platform offers growth opportunities in other areas regenerative medicine, beyond sky (space research) and beyond healthcare (tissues for industry) Established in 2017, CUTISS is a spin-off from University of Zurich (UZH) and University Children’s Hospital. Headquartered at the Bio-Technopark in Zurich, CUTISS won the Top 100 Swiss Startup Award 2020, and has raised over $90 million from private investors, family offices and public bodies.